|
 |
ColazalThis page contains recent news articles, when available, and an overview of Colazal but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Colazal (when available) Balsalazide is a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and 4-aminobenzoyl-(beta)-alanine. For the treatment of mildly to moderately active ulcerative colitis Mechanism Of Action: The mechanism of action of 5-aminosalicylic acid is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes and hydroxyeicosatetraenoic acids, is increased in patients with chronic inflammatory bowel disease, and it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon. News Articles on Balsalazide Possible Cause of Inflammatory Bowel Disease Uncovered - Dec 19, 2009 Colazal, developed by Salix Pharmaceuticals, is designed to treat mild to moderate forms of the disease. The company also markets the maintenance drug ... OneMedPlace (blog) Salix to File for IBS Indication - Analyst Blog - Dec 16, 2009 Rifaximin has taken over the role of primary growth driver following the introduction of generic versions of Colazal in December 2007 by three generic ... Benzinga Ulcerative Colitis- Drug Pipeline Analysis and Market Forecasts to 2015 - Dec 22, 2009 The others drugs like Apriso, Colazal, Pentasa and Lialda have moderate to high efficacy and safety and are fairly cost effective. ... Online PR News (press release) Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 ... - Oct 26, 2009 Colazal® is a registered trademark of Salix Pharmaceuticals, Inc. SOURCE Shire plc Blythe Bertolo of GolinHarris, +1-312-729-4463, for Shire; ... Reuters Salix Pharmaceuticals, Ltd. - Pharmaceuticals & Healthcare - Deals and ... - Nov 13, 2009 Oral Suspension DIURIL (Chlorothiazide); APRISO (mesalamine) extended-release capsules 0.375 grams, and COLAZAL (balsalazide disodium) Capsules 750 ... PR-inside.com (press release) Salix's Colazal Conundrum - Dec 31, 2007 As Salix Pharmaceuticals fights to keep its stronghold on the market for its anti-ulcer drug, investors are taking the better-safe-than-sorry route and ... Forbes … Pharmaceuticals doubles 3rd-quarter profit on higher sales of... - Nov 7, 2007 Revenue rose 32 percent to $67.4 million from $51.2 million, benefiting primarily from sales of Colazal, which climbed to $31.1 million from $27 million. msnbc.com Colazal Sanctioned for Pediatric Colitis - Dec 20, 2006 WEDNESDAY, Dec. 20 (HealthDay News) -- The US Food and Drug Administration has approved Colazal (balsalazide disodium) to treat mild-to-moderate ulcerative ... Washington Post ViroPharma Shares 'Absolute Floor' Seen At $9 to $10 - Mar 20, 2006 Colazal is a treatment for ulcerative colitis marketed by Salix Pharmaceuticals (nasdaq: SLXP - news - people ). The Piper Jaffray analyst cut the price ... Forbes Salix says higher dose of bowel drug effective - Jun 18, 2007 O) reported positive results from a late-stage trial of a higher dose of its drug, Colazal, for the treatment of a bowel disease called ulcerative colitis. ... Reuters Salix posts gain, first yearly profit. - Feb 16, 2005 Chief executive Carolyn Logan forecast that Colazal, Salix's best-selling drug, will generate at least $100 million in sales this year. ... Free with registration - News & Observer - AccessMyLibrary.com … American College of Gastroenterology COLAZAL(R) Update; COLAZAL( … - Jul 10, 2008 Patients were randomly selected to receive either COLAZAL or placebo. ... Patients receiving COLAZAL had relative reductions in each of the toxicity indices ... businesswire.com Generic charge pushes Salix into red - Mar 3, 2008 US regulators approved three companies' applications to sell generic versions of the company's best-selling treatment, ulcerative colitis drug Colazal. ... Bizjournals.com Crohn's Disease Medications - Crohn's Disease Health Information - NY... - Feb 20, 2008 ...including mesalamine (Asacol, Pentasa), olsalazine (Dipentum), and balsalazide (Colazal). These drugs, like sulfazine, are available as pills. ... New York Times … grants Salix Pharmaceuticals marketing exclusivity for granted... - Aug 28, 2006 Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. ... carolinanewswire.com Mylan gets approval for generic Colazal - Dec 31, 2007 Mylan Inc. received final approval from the US Food and Drug Administration to sell its balsalazide disodium capsules to treat ulcerative colitis, ... Pittsburgh Business Times … American College of Gastroenterology COLAZAL(R) Update; COLAZAL( … - Nov 1, 2005 Patients were randomly selected to receive either COLAZAL or placebo. ... Patients receiving COLAZAL had relative reductions in each of the toxicity indices ... RedOrbit Suprane, Colazal Need New Warnings on Heart, Lung Risks, FDA Staff … - Mar 24, 2008 Some Food & Drug Administration (FDA) advisors are pushing for new warnings on the labels of Suprane and Colazal because of potential risks these drugs may ... Newsinferno.com Colazal(R) Food Effect Application Granted FDA Approval - Sep 27, 2006 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announces that the US Food and Drug Administration approved a supplemental new drug application which provides for ... Genetic Engineering News - Genetic Engineering News (press release) NEW YORK, Dec 31 (Reuters) - US stocks on the move on Monday: - Dec 31, 2007 N) will market an authorized generic of its anti-inflammatory drug, Colazal. On Monday, Piper Jaffray cut its recommendation on Salix's stock to 'sell' from ... Reuters Colazal ® Pediatric Indication Approved - Jul 10, 2008 RALEIGH, NC--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the US Food and Drug Administration (FDA) has granted approval ... businesswire.com COLAZAL(R) Pediatric Exclusivity Filing Submitted. - Jul 5, 2006 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company submitted on June 20, 2006 what it believes to be a complete ... Free with registration - Business Wire - AccessMyLibrary.com Salix Announces Launch of COLAZAL(R) Authorized Generic with … - Dec 28, 2007 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that, pursuant to a supply and distribution agreement with Watson Pharma, Inc., ... Free with registration - Business Wire - AccessMyLibrary.com FDA won't approve Salix drug without another trial - Dec 29, 2008 The drug in question is a stronger form of Colazal, a 700-milligram capsule ... Colazal was Salix's best-seller until generic competition was introduced at ... Bizjournals.com Salix Announces Launch of COLAZAL® Authorized Generic with Watson - Dec 31, 2007 RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that, pursuant to a supply and distribution agreement with Watson Pharma, Inc., ... carolinanewswire.com Salix Pharmaceuticals Reports 1Q2005 Results; Total Product Revenue … - Mar 31, 2005 Sales of COLAZAL(R) generated product revenue of $23.8 million for the first ... I am pleased to announce that COLAZAL surpassed the one million mark in ... businesswire.com Q3 2006 Salix Pharmaceuticals, Inc. Earnings Conference Call - Final. - Nov 7, 2006 COLAZAL generated revenue of $27 million for the third quarter of 2006 ... COLAZAL prescriptions increased 9% year over year for the third quarter and 11% ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Salix swings to loss in 2Q - Aug 4, 2008 The company didn't break out revenue for Colazal in its second quarter earnings statements, but in the first quarter, revenue from the drug was $1.3 million ... Bizjournals.com Doctors score Colazal best journal ad.(Doctor's Choice Awards)(Brief ... - Nov 1, 2005 THE THIRD Annual Doctor's Choice Awards, held at Chelsea Piers in New York, October 11th, proved that it isn't necessarily the name on the shingle that ... Free with registration - Medical Marketing & Media - AccessMyLibrary.com Article: COLAZAL "FOOD EFFECT" APPLICATIOM GRANTED FDA … - Nov 1, 2006 COLAZAL "FOOD EFFECT" APPLICATIOM GRANTED FDA APPROVAL. ... find Biotech Business articles. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), Raleigh, NC, ... Pay-Per-View - Biotech Business - HighBeam Research Mylan drug to treat colitis - Jan 1, 2008 Colazal sales climbed to $31.1 million in the third quarter and accounted for nearly half of Salix's revenue. Mylan's generic version will enter the market ... Pittsburgh Post-Gazette - Pittsburgh Post Gazette Salix' Colazal gets extended exclusivity - Aug 30, 2006 North Carolina-based Salix Pharmaceuticals has been granted extended marketing exclusivity by the FDA for its ulcerative colitis drug, Colazal. ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Salix Pharmaceuticals Licenses OSMOPREP(TM) To Mayoly-Spindler in … - Oct 4, 2007 Salix markets COLAZAL® (balsalazide disodium) Capsules 750 mg, XIFAXAN® (rifaximin) tablets 200 mg , OSMOPREPâ„¢ (sodium phosphate monobasic monohydrate, ... RedOrbit Salix shares slide after FDA requests more data on drug - May 19, 2008 Salix sells balsalazide disodium in a 700-milligram capsule form under the trade name Colazal. The drug was the company's best-seller until generic ... Bizjournals.com Study: Salix drug helps treat radiation side effects - Aug 25, 2005 The results could open up a new use for Colazal, which currently is approved to treat ... The Colazal users also experienced fewer instances of fatigue, ... Triangle Business Journal Business Update; Colazal pediatric exclusivity granted for bowel... - Oct 1, 2006 2006 OCT 1 - (NewsRx.com) -- Salix Pharmaceuticals, Ltd. (SLXP) announced that the US Food and Drug Administration has granted Colazal additional marketing ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals,... - Sep 5, 2007 COLAZAL is indicated for the treatment of mildly to moderately active ulcerative colitis ... "We are pleased to be working with Salix to copromote COLAZAL, ... Free with registration - PR Newswire - AccessMyLibrary.com Salix buys drug rights from Dr. Falk Pharma - Mar 13, 2008 The company is seeking new products to offset slumping sales of its best-selling medicine, a treatment called Colazal. Salix shares rose 24 cents in midday ... News & Observer Article: Doctors score Colazal best journal ad.(Doctor's Choice... - Nov 1, 2005 Doctors score Colazal best journal ad.(Doctor's Choice Awards)(Brief Article) ... find Medical Marketing & Media articles. THE THIRD Annual Doctor's Choice ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Copycat would hurt Salix - Jul 18, 2006 But analysts project that by the end of the year, Colazal, Salix's ulcerative ... But Freeman pointed out the company is trying to protect Colazal sales. ... News & Observer Salix Pharmaceuticals to raise $50 million - Aug 18, 2008 Salix (Nasdaq: SLXP) has seen its business take a hit since the start of the year, when competitors began selling generic forms of Colazal – an inflammatory ... Bizjournals.com Morrisville, NC-based Salix Pharmaceuticals reports $3.4 million... - May 12, 2005 Colazal, a treatment for ulcerative colitis, generated $23.83 million in sales during the first quarter, up about 23 percent from a year ago. ... $9.94 - Knight Ridder/Tribune Business News - Alacra Store COLAZAL "FOOD EFFECT" APPLICATIOM GRANTED FDA APPROVAL. - Nov 1, 2006 Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), Raleigh, NC, has announced that the US Food and Drug Administration approved a supplemental new drug application ... Free with registration - Biotech Business - AccessMyLibrary.com BioDelivery's Sirgo joins Salix board - Feb 8, 2008 ...companies with more than one product on the market, recently said it expects to lose money this year thanks to generic competition for its drug Colazal. Bizjournals.com Colazal cleared for pediatric use by FDA.(Food and Drug Administration... - Jan 8, 2007 US drugmaker Salix Pharmaceuticals, a specialist developer of drugs for gastrointestinal diseases, says that the Food and Drug Administration has approved ... Free with registration - Pharma Marketletter - AccessMyLibrary.com InKine to be bought by Salix - Jun 24, 2005 The deal will bring the total number of drugs in Salix's portfolio to six, including Colazal, Xifaxan and Azasan, which Salix already markets. ... Philadelphia Business Journal Salix In-Licenses Crofelemer from Napo Pharmaceuticals - Dec 10, 2008 USP, and sodium phosphate dibasic anhydrous, USP) Tablets, COLAZAL ® (balsalazide disodium) Capsules 750 mg, PEPCID ® (famotidine) for Oral Suspension, ... International Business Times Salix Pharmaceuticals Reports Digestive Disease Week 2006 Update; … - May 22, 2006 Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. ... Free with registration - Business Wire - AccessMyLibrary.com New indication for Salix' balsalazide?(Salix Pharmaceuticals Inc.,... - Sep 5, 2005 ...in the latest issue of the International Journal of Radiation Oncology-Biology-Physics suggest that its drug Colazal (balsalazide disodium) may have the ... $4.95 - Pharma Marketletter - ECNext Colazal cleared.(RXs)(Salix Pharmaceuticals Inc.)(Brief article) - Jan 22, 2007 The FDA has approved Colazal as a treatment for children and teens with mildly to moderately active ulcerative colitis. Salix Pharmaceuticals Inc. is the ... Free with registration - Chain Drug Review - AccessMyLibrary.com Q4 2005 SALIX PHARMACEUTICALS INC Earnings Conference Call - … - Feb 24, 2006 During the fourth quarter of 2005, sales of the Colazal 500 count generated 7.4 million in revenue and sales of the Xifaxan 100 count generated 5.7 million ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Colazal.(Recently Approved) - Feb 1, 2007 Morrisville, NC-based Salix Pharmaceuticals Inc.'s ulcerative colitis drug Colazal (balsalazide disodium), which was previously approved for adult use, ... Free with registration - Pharmaceutical Representative - AccessMyLibrary.com Salix Pharmaceuticals Completes Merger with InKine Pharmaceutical; … - Oct 3, 2005 Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. ... $4.95 - Business Wire - ECNext Event Brief of Q2 2007 Salix Pharmaceuticals, Inc. Earnings Conference... - Aug 2, 2007 2Q07 COLAZAL revenue was $31.2m vs. $23.2m in 2Q06. 1. 1H07 COLAZAL revenue was $61.3m vs. $46.1m in 1H06. 2. Currently, annualized demand for COLAZAL is ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Salix to buy Philadelphia company for $190M - Jun 23, 2005 The deal will bring the total number of drugs in Salix's portfolio to six, including Colazal, Xifaxan and Azasan, which Salix already markets. ... Triangle Business Journal FDA approves treatment for children and teens with mildly to moderatel... - Dec 21, 2006 The Food and Drug Administration (FDA) today approved Colazal (balsalazide ... Pediatric use of Colazal was granted orphan drug status under FDA's Orphan ... Free with registration - M2 Presswire - AccessMyLibrary.com Personnel; Pharma company appoints VP, R&D and chief development … - Feb 11, 2005 ...granulated mesalamine for the maintenance of remission of ulcerative colitis, and to progress life cycle management programs for COLAZAL and XIFAXAN. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Eisai, Salix team up to push Colazal.(DIRECT MARKETING)(Brief... - Oct 1, 2007 Eisai, Salix team up to push Colazal.(DIRECT MARKETING)(Brief article) ... find Medical Marketing & Media articles. SALIX Pharmaceuticals and Eisai have ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Business Update; Colazal pediatric exclusivity granted for bowel... - Sep 29, 2006 2006 SEP 29 - (NewsRx.com) -- Salix Pharmaceuticals, Ltd. (SLXP) announced that the US Food and Drug Administration has granted Colazal additional marketing ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Zacks Bull and Bear of the Day Highlights: DeVry, Salix Pharmaceutical... - Nov 9, 2008 Salix Pharmaceuticals, Ltd. suffered a major setback late last year when the FDA granted approval to three generic versions of its lead product, Colazal. ... Ad-Hoc-News - Ad-Hoc-News (Pressemitteilung) Eisai, Salix team up to push Colazal. - Oct 1, 2007 Eisai, Salix team up to push Colazal. SALIX Pharmaceuticals and Eisai have entered into a multiyear co-promotion deal to promote Salix's ulcerative colitis ... $9.94 - Medical Marketing & Media - Alacra Store Salix Pharmaceuticals (SLXP) Submits NDA to FDA for Balsalazide Tablet - Jul 17, 2007 Balsalazide disodium is the active ingredient in COLAZAL Capsules 750 mg, the Company's anti-inflammatory drug approved and marketed for the treatment of ... StreetInsider.com - StreetInsider.com (subscription) Colazal.(NEW INDICATIONS) - Feb 5, 2007 Salix Pharmaceuticals, Raleigh, NC, (919) 862-1000, has been granted an expanded indication for Colazal (balsalazide disodium) tablets 750 mg, used to treat ... $4.95 - Drug Topics - ECNext Colazal. - Feb 5, 2007 Earlier approved for the treatment of adult patients, Colazal can now be used in patients aged five to 17 years of age. ... $9.94 - Drug Topics - Alacra Store Zacks Analyst Blog Highlights: Salix Pharmaceuticals, Ltd., AK Steel ... - Nov 25, 2008 The company suffered a major setback in December 2007 when the FDA granted approval to three generic versions of lead product, Colazal. ... International Business Times Article: Colazal cleared.(RXs)(Salix Pharmaceuticals Inc.)(Brief... - Jan 22, 2007 Colazal cleared.(RXs)(Salix Pharmaceuticals Inc.)(Brief article) ... find Chain Drug Review articles. The FDA has approved Colazal as a treatment for ... Pay-Per-View - Chain Drug Review - HighBeam Research Salix grows revenue, but profit shrinks on R&D costs - May 8, 2007 Sales of the company's top two products, ulcerative colitis treatment Colazal and travelers' diarrhea drug Xifaxan, jumped, as did sales of the company's ... Triangle Business Journal Colazal. - Feb 1, 2007 FDA approved balsalazide (Colazal, Salix) for the treatment of mildly to moderately active ulcerative colitis in patients aged 5 to 17 years. ... $9.94 - Formulary - Alacra Store Colazal cleared. - Jan 22, 2007 The FDA has approved Colazal as a treatment for children and teens with mildly to moderately active ulcerative colitis. Salix Pharmaceuticals Inc. is the ... $9.94 - Chain Drug Review - Alacra Store Colazal.(FDA actions in brief)(Brief article) - Feb 1, 2007 FDA approved balsalazide (Colazal, Salix) for the treatment of mildly to moderately active ulcerative colitis in patients aged 5 to 17 years. $4.95 - Formulary - ECNext Salix Pharmaceuticals to Present at Rodman & Renshaw Global … - Apr 27, 2005 Salix markets COLAZAL(R), XIFAXAN(TM), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated mesalamine product also is under development. ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports 1Q2006 Results - Mar 31, 2006 COLAZAL generated revenue of $22.8 million for the first quarter of 2006 compared to ... At year-end we anticipate COLAZAL and XIFAXAN inventories will be ... businesswire.com Colazal cleared for pediatric use by FDA - Jan 3, 2007 US drugmaker Salix Pharmaceuticals, a specialist developer of drugs for gastrointestinal diseases, says that the Food and Drug Administration has approved ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones … and generic drug approvals: colazal (balsalazide disodium)... - Dec 27, 2006 On 27 Dec 2006, the US Food and Drug Administration announced approval of NDA 020610 for colazal (balsalazide disodium) capsules. ... Pay-Per-View - US Food and Drug Administration News - Factiva, from Dow Jones Salix Pharmaceuticals to Present at Bank of America Conference. - Aug 8, 2006 Salix markets COLAZAL(R), XIFAXAN(R), VISICOL(R), OSMOPREP(TM), MOVIPREP(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). Granulated mesalamine is under ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Announces Submission Of Balsalazide Tablet … - Jul 19, 2007 According to Salix, balsalazide disodium is the active ingredient in Colazal 750 mg, Salix's anti–inflammatory drug approved and marketed for the treatment ... FDA news - FDA news (subscription) Fayetteville Observer, The : In brief - Dec 21, 2006 RALEIGH — The Food and Drug Administration has approved of the use of Colazal in patients ages 5-17 to treat colitis. The anti-inflammatory drug is approved ... $2.95 - Fayetteville Observer - NewsBank Pre-Open Movers 12/31: Delta Petroleum (DPTR) Up On Kerkorian Stake, … - Dec 31, 2007 Salix Pharmaceuticals Ltd. (Nasdaq: SLXP) 8% LOWER; Mylan (NYSE: MYL) gets FDA okay for generic Colazal. Baidu.com, Inc. (Nasdaq: BIDU) 1% LOWER; ... StreetInsider.com - StreetInsider.com (subscription) Salix Pharmaceuticals to Present At UBS Conference. - Sep 21, 2005 Salix markets COLAZAL(R), XIFAXAN(R), AZASAN(R), ANUSOL-HC(R) and PROCTOCORT(R). A granulated mesalamine product also is under development. ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports 2Q2006 Results. - Aug 8, 2006 COLAZAL(R) generated revenue of $23.2 million for the second quarter of 2006 ... COLAZAL generated revenue of $46.1 million for the first six months of 2006 ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 23, 2006 Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Reports 4Q2006 and FY2006 Results.(Financial … - Feb 28, 2007 COLAZAL generated revenue of $103.5 million for 2006 compared to $110.3 ... This 6% decrease in revenue compared to 2005 COLAZAL revenue reflects the ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 23, 2006 XIFAXAN([R]), COLAZAL([R]), OSMOPREP[TM], VISICOL([R]) and MOVIPREP([R]) RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported on results ... $4.95 - Business Wire - ECNext UBC Late Stage alleges Salix Pharmaceuticals won't pay trials bills - May 2, 2008 Gust expects the FDA to approve a once-a-day version of Colazal in May 2008. Approval for another Salix product similar to Colazal could come by year's end. ... Bizjournals.com Salix Pharmaceuticals Reports Digestive Disease Week 2006 Update; … - Jul 10, 2008 Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. ... businesswire.com Salix Pharma第四å£ç›ˆä½™ä¸Žè?¥æ”¶å?‡èŽ·æˆ?é•¿ - Feb 15, 2005 ...å…¶ä¸Colazal销售é¢?æˆ?长了53%，至2640万美元。 这一制è?¯å•†é¢„期2005å¹´æ¯?股盈余å?¯è¾¾60美 分，è?¥æ”¶å?¯è¾¾1亿5000万至1亿5500万美元。Thomson First Call调查的分æž?师当å‰?å¹³å?‡ ... 新浪网 Press Release: Eisai Inc. Enters Copromotion Agreement with Salix … - Sep 5, 2007 COLAZAL is indicated for the treatment of mildly to moderately active ulcerative colitis ... "We are pleased to be working with Salix to copromote COLAZAL, ... Pay-Per-View - PR Newswire - HighBeam Research Morrisville, NC-based specialty drug maker earnings exceed expectation... - Nov 9, 2005 The company's best-selling drug, Colazal, is likely to encounter competition ... Colazal, a treatment for ulcerative colitis, generated more than 70 percent ... Free with registration - News & Observer - AccessMyLibrary.com Salix requests more exclusivity. - Jul 6, 2006 6--MORRISVILLE -- Salix Pharmaceuticals is asking federal regulators to extend the market exclusivity of its best-selling drug, Colazal, by about six months ... Free with registration - News & Observer - AccessMyLibrary.com Press Release: FDA approves treatment for children and teens with... - Dec 21, 2006 The Food and Drug Administration (FDA) today approved Colazal (balsalazide ... Pediatric use of Colazal was granted orphan drug status under FDA's Orphan ... Pay-Per-View - M2 Presswire - HighBeam Research Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 23, 2006 XIFAXAN([R]), COLAZAL([R]), OSMOPREP[TM], VISICOL([R]) and MOVIPREP([R] )Sunday, October 22 Poster Presentation Highlights. $4.95 - Business Wire - ECNext Zacks Analyst Blog Highlights: Xoma, Novartis, Salix Pharmaceuticals ... - Mar 5, 2007 Colazal is likely to face intense competition with the entry of Shire's ... The inventory situation together with the low visibility on Colazal will ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 24, 2006 Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. ... Free with registration - Business Wire - AccessMyLibrary.com Salix Pharmaceuticals Development Update; XIFAXAN(R) Trials Initiated... - Jan 11, 2006 COLAZAL (balsalazide disodium), formulated as an 1100 mg tablet, dosed three tablets twice daily ... COLAZAL(R) (balsalazide disodium) Capsules 750 mg is an ... RedOrbit Salix Pharmaceuticals Reports 2Q2005 Results; Total Product Revenue … - Jun 30, 2005 Sales of COLAZAL(R) generated product revenue of $26.8 million for the second ... COLAZAL continued to grow during the second quarter of 2005 and monthly ... businesswire.com Q4 2004 SALIX PHARMACEUTICALS INC Earnings Conference Call - … - Feb 15, 2005 Just getting a sense on Colazal, following up on last question, can you give us a level of inventory on Colazal at the end of Q4? Free with registration - America's Intelligence Wire - AccessMyLibrary.com GETTING AHEAD | Article from The Record (Bergen County, NJ) | … - Sep 6, 2007 An article Thursday implied that Colazal had not been approved by federal ... The drug Colazal is indicated for the treatment of mildly to moderately active ... Pay-Per-View - The Record - HighBeam Research Salix Pharmaceuticals Reports American College of Gastroenterology … - Oct 24, 2006 XIFAXAN([R]), COLAZAL([R]), OSMOPREP[TM], VISICOL([R]) and MOVIPREP([R]) RALEIGH, NC -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported on results ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Reports 2Q2005 Results; Total Product Revenue … - Aug 9, 2005 Sales of COLAZAL(R) generated product revenue of $26.8 million for the second ... COLAZAL continued to grow during the second quarter of 2005 and monthly ... $4.95 - Business Wire - ECNext Salix Pharmaceuticals Announces American College of Gastroenterology ... - Oct 16, 2006 XIFAXAN(R), COLAZAL(R), OSMOPREP(TM), VISICOL(R) and MOVIPREP(R) Studied in Investigator-Initiated and Company-Sponsored Trials. $4.95 - Business Wire - ECNext Ulcerative colitis treatment for children and teens.(Updates)(Salix … - Mar 1, 2007 Colazal (balsalazide disodium) has been approved for the treatment of mildly to ... Pediatric use of Colazal was granted orphan drug status in December 2006 ... $4.95 - FDA Consumer - ECNext Shares slip after Salix warns of losses - Jan 31, 2008 The announcement came after US regulators approved three companies' applications to sell generic versions of Salix's best-selling treatment, Colazal, ... Bizjournals.com Salix Pharmaceuticals Reports 1Q2006 Results - May 4, 2006 COLAZAL generated revenue of $22.8 million for the first quarter of 2006 compared to $23.8 million for the first quarter of 2005, as prescriptions grew 9% ... Genetic Engineering News - Genetic Engineering News (press release) Salix Pharmaceuticals Announces Positive Top Line Results of … - Jul 31, 2007 Balsalazide disodium is the active ingredient in COLAZAL ® Capsules 750 mg ... Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. ... businesswire.com Salix Pharmaceuticals Announces Submission of Balsalazide Tablet New … - Jul 17, 2007 Safety and effectiveness of COLAZAL beyond 12 weeks has not been established. COLAZAL was well tolerated in clinical studies. ... Free with registration - Business Wire - AccessMyLibrary.com Brand Names/Synonyms: Colazal is also known by the following brand names and/or synonymsBALSALAZIDE; Balsalazida [Spanish]; Balsalazide Disodium; Balsalazido [Spanish]; Balsalazidum [Latin]; Carbadox; Colazal Drug Category: Colazal is categorized under the following by the FDA: Anti-ulcer Agents; ATC:A07EC04 Dosage Forms: Not Available Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 5-[4-(2-carboxyethylcarbamoyl)phenyl]azo-2-hydroxy-benzoicacid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |